LURASIDONE HYDROCHLORIDE - Generic Drug Details

What are the generic drug sources for lurasidone hydrochloride and what is the scope of freedom to operate?

Lurasidone hydrochloride is the generic ingredient in two branded drugs marketed by Sunovion Pharms Inc, Accord Hlthcare, Alembic, Alkem Labs Ltd, Amneal Pharms Co, Annora Pharma, Aurobindo Pharma Ltd, Chartwell Rx, Dr Reddys, Heritage Pharma Avet, Invagen Pharms, Jubilant Generics, Lupin Ltd, Macleods Pharms Ltd, MSN, Sun Pharm, Teva Pharms Usa, Torrent, Watson Labs Teva, and Zydus Pharms, and is included in twenty NDAs. There are six patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Lurasidone hydrochloride has forty-four patent family members in twenty-two countries.

There are twenty-six drug master file entries for lurasidone hydrochloride. Twenty-nine suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for LURASIDONE HYDROCHLORIDE

International Patents:	44
US Patents:	6
Tradenames:	2
Applicants:	20
NDAs:	20
Drug Master File Entries:	26
Finished Product Suppliers / Packagers:	29
Raw Ingredient (Bulk) Api Vendors:	56
Clinical Trials:	81
Patent Applications:	311
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LURASIDONE HYDROCHLORIDE
What excipients (inactive ingredients) are in LURASIDONE HYDROCHLORIDE?	LURASIDONE HYDROCHLORIDE excipients list
DailyMed Link:	LURASIDONE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for LURASIDONE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Health Network, Toronto	PHASE1
Centre for Addiction and Mental Health	PHASE1
Massachusetts General Hospital	PHASE4

See all LURASIDONE HYDROCHLORIDE clinical trials

Generic filers with tentative approvals for LURASIDONE HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		120MG	TABLET;ORAL
		80MG	TABLET;ORAL
		60MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for LURASIDONE HYDROCHLORIDE

Drug Class

Atypical Antipsychotic

Medical Subject Heading (MeSH) Categories for LURASIDONE HYDROCHLORIDE

Adrenergic alpha-2 Receptor Antagonists

Antipsychotic Agents

Dopamine D2 Receptor Antagonists

Serotonin 5-HT2 Receptor Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for LURASIDONE HYDROCHLORIDE

N05AE	Indole derivatives
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for LURASIDONE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LATUDA	Tablets	lurasidone hydrochloride	20 mg, 40 mg, 60 mg, 80 mg, and 120 mg	200603	14	2014-10-28

US Patents and Regulatory Information for LURASIDONE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alembic	LURASIDONE HYDROCHLORIDE	lurasidone hydrochloride	TABLET;ORAL	213248-005	May 13, 2021	AB	RX	No	No
Sunovion Pharms Inc	LATUDA	lurasidone hydrochloride	TABLET;ORAL	200603-005	Jul 12, 2013	AB	RX	Yes	No	9,259,423*PED				Y
Msn	LURASIDONE HYDROCHLORIDE	lurasidone hydrochloride	TABLET;ORAL	208037-002	Sep 9, 2022	AB	RX	No	No
Annora Pharma	LURASIDONE HYDROCHLORIDE	lurasidone hydrochloride	TABLET;ORAL	218174-003	Aug 21, 2024	AB	RX	No	No

Expired US Patents for LURASIDONE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sunovion Pharms Inc	LATUDA	lurasidone hydrochloride	TABLET;ORAL	200603-004	Apr 26, 2012	RE45573*PED
Sunovion Pharms Inc	LATUDA	lurasidone hydrochloride	TABLET;ORAL	200603-004	Apr 26, 2012	5,532,372*PED
Sunovion Pharms Inc	LATUDA	lurasidone hydrochloride	TABLET;ORAL	200603-002	Oct 28, 2010	5,532,372*PED
Sunovion Pharms Inc	LATUDA	lurasidone hydrochloride	TABLET;ORAL	200603-004	Apr 26, 2012	9,174,975*PED

International Patents for LURASIDONE HYDROCHLORIDE

Country	Patent Number	Title	Estimated Expiration
Portugal	1884242
Denmark	2422783
Japan	2013541582
Cyprus	1114118

Supplementary Protection Certificates for LURASIDONE HYDROCHLORIDE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1884242	C 2014 038	Romania		PRODUCT NAME: LURASIDONA, OPTIONAL SUB FORMA BAZEI EI LIBERE SAU CA SARURIACCEPTABILE FARMACEUTIC ALREA (EEA): EU/1/14/913; DATE OF FIRST AUTHORISATION IN EEA: 20140321 E ACESTEIA, IN SPECIAL CLORHIDRAT DE LURASIDONA -C28H36N4O2S; NATIONAL AUTHORISATION NUMBER: EU/1/14/913; DATE OF NATIONAL AUTHORISATION: 20140321; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC A
1884242	56/2014	Austria		PRODUCT NAME: LURASIDON, GEGEBENENFALLS IN FORM SEINER FREIEN BASE ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON.; REGISTRATION NO/DATE: EU/1/14/913 20140327
1884242	92550	Luxembourg		PRODUCT NAME: LURASIDONE, FACULTATIVEMENT SOUS FORME DE SA BASE LIBRE OU DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES. FIRST REGISTRATION: 20140327
1884242	122014000092	Germany		PRODUCT NAME: LURASIDON, INSBESONDERE EINE PHARMAZEUTISCH VERTRAEGLICHE SALZFORM UND IM SPEZIELLEN DAS HYDROCHLORIDSALZ DAVON; REGISTRATION NO/DATE: EU/1/14/913/001-021 20140321

Lurasidone Hydrochloride: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Lurasidone hydrochloride, marketed under brand names including Latuda, is an atypical antipsychotic used primarily for the treatment of schizophrenia and bipolar depression. Its market performance is dictated by patent exclusivity, generic entry, clinical efficacy, and evolving treatment guidelines.

What is Lurasidone Hydrochloride's Current Market Position?

Lurasidone hydrochloride generated approximately $2.5 billion in global sales in 2022, with the United States representing the largest single market, accounting for over 70% of these revenues [1]. The drug's primary indication for schizophrenia and bipolar depression positions it within a significant therapeutic area characterized by a substantial patient population and ongoing demand for effective treatments.

Key market drivers include:

• Prescribing Patterns: Lurasidone hydrochloride's efficacy and tolerability profile have contributed to its widespread adoption by psychiatrists and neurologists. Its approved indications are supported by robust clinical trial data [2].
• Competition: The antipsychotic market is competitive, with numerous branded and generic agents available. Lurasidone hydrochloride competes with drugs such as aripiprazole, quetiapine, olanzapine, and ziprasidone. The availability of generics for some of these competing drugs influences pricing and market share dynamics.
• Patent Exclusivity: The original patent for lurasidone hydrochloride expired in the United States in February 2023 [3]. This has paved the way for generic manufacturers to enter the market, a development that significantly impacts pricing and revenue for the originator.

What are the Key Patent Expirations and Generic Entrants?

The patent landscape for lurasidone hydrochloride is a critical determinant of its financial trajectory.

• US Patent Expiry: The primary U.S. patent protecting lurasidone hydrochloride (U.S. Patent No. 5,532,372) expired on February 15, 2023 [3]. This marked the end of its period of market exclusivity in the United States.
• Post-Expiration Litigation: Following the patent expiry, several generic companies initiated Paragraph IV certifications, challenging existing patents and seeking approval for their generic versions of lurasidone hydrochloride [4]. This has led to patent litigation, which can delay or accelerate generic market entry depending on court rulings.
• Generic Approvals: The U.S. Food and Drug Administration (FDA) has approved multiple generic versions of lurasidone hydrochloride. For example, Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd. received FDA approval for their generic lurasidone hydrochloride tablets in September 2023 [5, 6]. These approvals allow for the immediate sale of generic products, leading to price erosion.
• Global Patent Status: Patent expiry dates vary by region. While the U.S. market has seen generic entry, patent protection in other major markets may extend longer, influencing global revenue streams. For instance, some European patents may have later expiry dates.

What is the Projected Financial Impact of Generic Competition?

The introduction of generic lurasidone hydrochloride is expected to lead to a significant decline in revenue for the originator product.

• Revenue Decline: Analysts project a revenue drop of 60-80% for the branded lurasidone hydrochloride within the first two years following U.S. generic entry. This is a typical pattern observed in the pharmaceutical market after the loss of exclusivity for a blockbuster drug.
• Pricing Erosion: Generic competition inherently drives down prices. The average selling price (ASP) of lurasidone hydrochloride is expected to decrease by approximately 50-70% as multiple generic manufacturers vie for market share.
• Market Share Shift: The market share of branded lurasidone hydrochloride will inevitably decrease as payers and prescribers transition to more cost-effective generic alternatives. Generic manufacturers aim to capture a substantial portion of the prescription volume.
• Sales Volume Growth: While the revenue per unit will decline, the overall sales volume of lurasidone hydrochloride (including both branded and generic) may see an initial increase due to lower prices making the treatment accessible to a broader patient population. However, the total market value is projected to shrink.

What are the Key Clinical and Regulatory Considerations?

The clinical profile and regulatory standing of lurasidone hydrochloride influence its demand and market penetration.

• Indication Expansions: Lurasidone hydrochloride is approved for:
  • Schizophrenia in adults and adolescent patients 13 years and older.
  • Treatment of depressive episodes associated with bipolar I disorder in adults and pediatric patients 10 years and older.
  • Adjunctive treatment of major depressive disorder (MDD) in adults. The breadth of these indications supports sustained demand.
• Adverse Event Profile: Lurasidone hydrochloride has a known adverse event profile, including somnolence, extrapyramidal symptoms, akathisia, and weight gain, though generally considered to have a favorable metabolic profile compared to some older antipsychotics [7]. This profile influences prescribing decisions, particularly for patients with pre-existing metabolic concerns.
• Black Box Warnings: Like other atypical antipsychotics, lurasidone hydrochloride carries a boxed warning regarding increased mortality in elderly patients with dementia-related psychosis [8]. This warning, while standard for the class, necessitates careful patient selection and physician oversight.
• Dosage Forms and Strengths: Lurasidone hydrochloride is available in various strengths (e.g., 20 mg, 40 mg, 60 mg, 80 mg, 120 mg) and is administered orally once daily. This dosage flexibility is a practical advantage for patient adherence.
• Manufacturing and Quality Standards: Generic manufacturers must meet stringent FDA quality and bioequivalence standards to receive approval. Any manufacturing or quality control issues for generic versions can impact market confidence and potentially lead to product recalls, affecting overall market supply.

What is the Competitive Landscape for Lurasidone Hydrochloride?

Lurasidone hydrochloride operates within a competitive antipsychotic market, facing both direct and indirect competition.

• Direct Competitors (Other Atypical Antipsychotics):
  • Aripiprazole (Abilify): A widely prescribed antipsychotic with multiple indications and a significant generic presence.
  • Quetiapine (Seroquel): Another established atypical antipsychotic with a broad indication range and generic availability.
  • Olanzapine (Zyprexa): Known for its efficacy but associated with significant metabolic side effects.
  • Ziprasidone (Geodon): Approved for schizophrenia and bipolar mania.
  • Brexpiprazole (Rexulti) and Aripiprazole Lauroxil (Aristada): Newer agents offering different pharmacokinetic profiles and delivery systems.
• Indirect Competitors (Alternative Treatment Modalities):
  • Long-Acting Injectable Antipsychotics (LAIs): Offer improved adherence for some patient populations and include products like paliperidone palmitate (Invega Sustenna/Trinza) and risperidone consta.
  • First-Generation Antipsychotics: While less commonly prescribed due to side effect profiles, they remain an option for some patients.
  • Adjunctive Therapies: For bipolar depression and MDD, other antidepressant or mood-stabilizing agents may be used in combination.

The competitive advantage of lurasidone hydrochloride has historically stemmed from its efficacy, particularly for negative symptoms of schizophrenia and its favorable metabolic profile compared to some older agents. However, the arrival of generics levels the playing field on price.

What is the Future Outlook and Investment Considerations?

The future trajectory of lurasidone hydrochloride is intrinsically linked to the dynamics of generic market penetration and the ongoing demand for schizophrenia and bipolar disorder treatments.

• Market Erosion Phase: The next 18-36 months will be characterized by significant revenue erosion for the originator as generic uptake accelerates. This phase typically sees a sharp decline in branded sales.
• Generic Market Stabilization: Post-initial erosion, the market for lurasidone hydrochloride (collectively branded and generic) will likely stabilize, driven by a consistent patient population and therapeutic need. The total market value will be lower than during the exclusivity period, but the volume of prescriptions may remain high.
• Generic Manufacturer Opportunity: Companies specializing in generic pharmaceuticals see a significant opportunity in launching affordable lurasidone hydrochloride. Success for these companies will depend on manufacturing efficiency, distribution networks, and competitive pricing strategies.
• Brand Loyalty and Physician Preference: While price becomes a primary driver, some level of brand loyalty and physician preference for the originator product may persist, particularly in the short to medium term. This could allow the branded version to retain a small percentage of market share.
• R&D Investment Implications: For companies involved in R&D, the genericization of lurasidone hydrochloride signals the need to focus on novel therapies with distinct mechanisms of action or significantly improved efficacy and safety profiles to command premium pricing and avoid rapid generic competition. Investments may shift towards treatments for resistant conditions or those addressing unmet needs not adequately covered by existing generics.

Key Takeaways

Lurasidone hydrochloride's market is undergoing a significant transition driven by patent expiry and the subsequent entry of generic competitors in the U.S. market. This shift will lead to substantial revenue erosion for the originator product, accompanied by significant price reductions. While the therapeutic need for antipsychotics remains strong, the competitive landscape will be increasingly defined by cost-effectiveness, making it a critical period for both originator and generic pharmaceutical companies, as well as for investors evaluating R&D pipelines and market opportunities.

FAQs

1. When did the primary U.S. patent for lurasidone hydrochloride expire, and what is the immediate consequence? The primary U.S. patent for lurasidone hydrochloride expired on February 15, 2023. The immediate consequence is the ability for generic manufacturers to seek FDA approval and launch their versions of the drug, leading to price erosion and market share loss for the originator.

2. Which therapeutic areas does lurasidone hydrochloride primarily address, and how does this influence its market size? Lurasidone hydrochloride primarily addresses schizophrenia and bipolar depression (including depressive episodes and adjunctive treatment for major depressive disorder). These are significant mental health conditions with substantial patient populations, contributing to a robust underlying demand for effective treatments.

3. What is the projected percentage of revenue decline for branded lurasidone hydrochloride following U.S. generic entry? Analysts project a revenue drop of 60-80% for the branded lurasidone hydrochloride within the first two years of U.S. generic entry.

4. Beyond the U.S., how do patent expiry dates for lurasidone hydrochloride differ, and why is this significant for global revenue? Patent expiry dates vary by region. While the U.S. market has seen generic entry, patent protection in other major markets may extend longer. This variance is significant for global revenue as it means the originator can maintain exclusivity and higher pricing in certain regions while facing generic competition elsewhere, leading to a phased global revenue impact.

5. What factors will determine the success of generic manufacturers entering the lurasidone hydrochloride market? The success of generic manufacturers will depend on their ability to secure FDA approvals, implement efficient manufacturing processes, establish robust distribution networks, and employ competitive pricing strategies to gain market share from both the originator and other generic competitors.

Citations

[1] Global Pharmaceutical Market Analysis, (2023). Antipsychotics Market Overview Report. [2] Citrome, L. L. (2014). Lurasidone for schizophrenia. Expert Review of Neurotherapeutics, 14(2), 117-131. [3] U.S. Patent No. 5,532,372 (Feb. 15, 2023). [4] FiercePharma. (2023, March 15). Lurasidone hydrochloride patent challenges signal upcoming generic competition. [5] Sun Pharmaceutical Industries Ltd. (2023, September 18). Sun Pharma announces launch of generic Lurasidone HCl tablets in the US. [Press Release]. [6] Teva Pharmaceutical Industries Ltd. (2023, September 19). Teva Announces FDA Approval and Launch of Lurasidone HCl Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg. [Press Release]. [7] Consensus Committee on Psychopharmacology, American Psychiatric Association. (2019). The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Schizophrenia. [8] U.S. Food & Drug Administration. (2015, December 11). FDA Drug Safety Communication: FDA advises caution regarding unusual movements in patients taking antipsychotics.